Elypta awarded €2.35 million from Horizon 2020 SME instrument

Elypta today announced it is one of the winners in the European Union’s Horizon 2020 Research and Innovation Programme SME instrument phase 2 and has been awarded Euros 2.35 m. The grant will fund the first ever multicenter trial for diagnoses of renal cell carcinoma (RCC), aimed at validating the company's innovative metabolism-based liquid biopsy platform for early detection of recurrent RCC and thus enabling the test to be launched in Europe and the US.

Swedish press release

Select press coverage:

Nordic Life Science

Life Science Sweden



Karl Bergman